Exact Therapeutics AS
OSE:EXTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Exact Therapeutics AS
Long-Term Debt
Exact Therapeutics AS
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Exact Therapeutics AS
OSE:EXTX
|
Long-Term Debt
kr52.4k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Long-Term Debt
kr1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Long-Term Debt
kr4.2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Long-Term Debt
$1.3m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
177%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Long-Term Debt
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Long-Term Debt
kr159.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
103%
|
CAGR 10-Years
N/A
|
|
Exact Therapeutics AS
Glance View
EXACT Therapeutics AS is a clinical stage biopharmaceutical company, which engages in the research and development of novel platform for ultrasound mediated therapeutic amplification. The company is headquartered in Oslo, Oslo and currently employs 8 full-time employees. The company went IPO on 2020-07-14. ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The firm's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. The company is done through harnessing the power of ultrasound in combination with ACT formulation.
See Also
What is Exact Therapeutics AS's Long-Term Debt?
Long-Term Debt
52.4k
NOK
Based on the financial report for Dec 31, 2024, Exact Therapeutics AS's Long-Term Debt amounts to 52.4k NOK.
What is Exact Therapeutics AS's Long-Term Debt growth rate?
Long-Term Debt CAGR 1Y
-92%
Over the last year, the Long-Term Debt growth was -92%.
